Live

Stocks get clobbered as Trump's China trade war intensifies. See the latest.

NasdaqGM - Nasdaq Real Time Price USD

Mirum Pharmaceuticals, Inc. (MIRM)

Compare

39.12

-2.35

(-5.67%)

At close: 4:00:02 PM EDT

39.12

0.00

(0.00%)

After hours: 4:05:07 PM EDT

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 7 days ago

RNA

MIRM
-5.67%
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 13 days ago

MIRM
-5.67%
KRYS
-4.47%
LIVMARLI Now Approved in Japan for ALGS and PFIC

FOSTER CITY, Calif., March 27, 2025--LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire 14 days ago

MIRM
-5.67%
Exploring 3 High Growth Tech Stocks in the US Market

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion within a stable and upward-trending market environment.

Simply Wall St. 17 days ago

ALKT

MIRM
-5.67%
INTA
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 11, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 30 days ago

MIRM
-5.67%
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Last week, you might have seen that Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) released its yearly result to the...

Simply Wall St. last month

MIRM
-5.67%
Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Mirum Pharmaceuticals ( NASDAQ:MIRM ) Full Year 2024 Results Key Financial Results Revenue: US$336.9m (up 81% from FY...

Simply Wall St. last month

MIRM
-5.67%
Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

MIRM
-5.67%
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks last month

MIRM
-5.67%
Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum Pharmaceuticals Inc (MIRM) reports a 43% increase in Q4 net product sales, driven by strong demand for LIVMARLI and strategic market expansions.

GuruFocus.com last month

MIRM
-5.67%
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MIRM
-5.67%
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

FOSTER CITY, Calif., February 26, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update.

Business Wire last month

MIRM
-5.67%
Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […]

Insider Monkey last month

MIRM
-5.67%
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

MIRM
-5.67%
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

FOSTER CITY, Calif., February 24, 2025--Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Business Wire last month

MIRM
-5.67%
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

FOSTER CITY, Calif., February 19, 2025--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Business Wire last month

MIRM
-5.67%
High Growth Tech Stocks in United States to Watch

The United States market has shown a positive trend, rising 1.2% over the last week and 24% over the past year, with earnings expected to grow by 15% annually. In this context of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability in an evolving market landscape.

Simply Wall St. last month

DOCN

KRYS
-4.47%
MIRM
-5.67%
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

MIRM
-5.67%
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.

Zacks 2 months ago

MIRM
-5.67%
Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high-growth tech stocks that can capitalize on such robust earnings growth potential becomes essential for investors seeking opportunities in a dynamic market environment.

Simply Wall St. 2 months ago

MSI

MIRM
-5.67%
ENFN

Performance Overview

Return	MIRM	S&P 500 (^GSPC)
YTD	-5.39%	-10.43%
1-Year	+52.63%	+2.08%
3-Year	+42.46%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Mirum Pharmaceuticals, Inc. (MIRM)

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

LIVMARLI Now Approved in Japan for ALGS and PFIC

Exploring 3 High Growth Tech Stocks in the US Market

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

High Growth Tech Stocks in United States to Watch

Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Exploring Three High Growth Tech Stocks in the United States

Performance Overview